PD-1, PD-L1 and PD-L2 Gene Expression on T-Cells and Natural Killer Cells Declines in Conjunction with a Reduction in PD-1 Protein during the Intensive Phase of Tuberculosis Treatment

PLoS One. 2015 Sep 11;10(9):e0137646. doi: 10.1371/journal.pone.0137646. eCollection 2015.

Abstract

Background: The PD-1 axis is a cell intrinsic immunoregulatory pathway that mediates T cell exhaustion in chronic infection particularly in some viral infections. We hypothesized that PD-1, PD-L1 and PD-L2 would be highly expressed in untreated tuberculosis patients compared to controls due to their chronic infection and would decrease with successful TB treatment.

Materials and methods: Untreated tuberculosis patients (n = 26) were recruited at diagnosis and followed up during treatment. Household contacts (n = 24) were recruited to establish baseline differences. Blood gene expression ex vivo was investigated using qRT-PCR. Flow cytometry was performed to establish protein expression patterns.

Results: PD-L1 gene expression was found to be elevated in active TB disease; however, this was not observed for PD-1 or PD-L2. The intensive phase of TB treatment was associated with a significant decline in PD-1, PD-L1 and PD-L2 gene expression. PD-1 protein expression on the surface of NK cells, CD8+ and CD4+ T cells was similar in patients with active TB disease compared to controls but declined with successful TB treatment, with the greatest decline occurring on the NK cells followed by CD8+ T cells and then CD4+ T cells. Granzyme B/PD-1 co-expression declined with successful intensive phase treatment.

Conclusion: Modulation of PD-1/PD-L1 pathway through TB treatment indicates changes in the peripheral T cell response caused by live Mycobacterium tuberculosis (Mtb) followed by the response to dead bacilli, antigen-release and immuno-pathology resolution. The PD-1 axis could be a host drug target for immunomodulatory treatments in the future.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antitubercular Agents / therapeutic use
  • B7-H1 Antigen / genetics*
  • B7-H1 Antigen / metabolism
  • Down-Regulation
  • Female
  • Gene Expression Regulation
  • Humans
  • Immunophenotyping
  • Killer Cells, Natural / immunology
  • Killer Cells, Natural / metabolism*
  • Lymphocyte Count
  • Male
  • Middle Aged
  • Mycobacterium tuberculosis*
  • Programmed Cell Death 1 Ligand 2 Protein / genetics*
  • Programmed Cell Death 1 Ligand 2 Protein / metabolism
  • Programmed Cell Death 1 Receptor / genetics*
  • Programmed Cell Death 1 Receptor / metabolism
  • T-Lymphocyte Subsets / immunology
  • T-Lymphocyte Subsets / metabolism*
  • Tuberculosis / drug therapy
  • Tuberculosis / genetics*
  • Tuberculosis / immunology
  • Tuberculosis / metabolism*
  • Young Adult

Substances

  • Antitubercular Agents
  • B7-H1 Antigen
  • Programmed Cell Death 1 Ligand 2 Protein
  • Programmed Cell Death 1 Receptor

Grants and funding

This work was supported by the University of London Central Research Fund (Grant # AR/CRF/B), http://www.london.ac.uk/awards_pg.html. Salary support for JMC was provided by the EDCTP (Grant: IP.2009.32040.011), http://www.edctp.org/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.